This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
DosingEfficacy & Safety Data Efficacy &
Safety Data 
EfficacySafety Profile
Search

Menu

Close

SavingsSamplesCoverageResourcesResourcesMaterialsVideos
Prescribing Information, including BOXED WARNINGPatient InformationIndicationPatient Site
EventsMaterialsVideos
Explore Other MaterialsClear filters
{{format}}
{{{title}}} {{#if duration}}

{{duration}}

{{/if}}
{{{cardSummary}}}{{{description}}} {{#if piMessage}}
{{{piMessage}}}
{{/if}}
>
{{#if jobBagNumber}}
{{{jobBagNumber}}}
{{/if}}
No content is currently available

Check back soon to see if new materials have been added, or try looking for another brand or therapy area.

Reset Filters
EventsMaterialsVideos
Explore Other MaterialsClear filters
This is the content when there are items.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-PVC-USA-0933
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. PP-MCL-USA-0367

​​​​​​​
INDICATION Premarin® (conjugated estrogens) Vaginal Cream is indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
Important Safety Information

There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia.

The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women with daily oral conjugated estrogens (CE) alone. The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism, stroke, and myocardial infarction in postmenopausal women with daily oral CE combined with medroxyprogesterone acetate (MPA). In the absence of comparable data, these risks should be assumed to be similar for other dosage forms of estrogens.

The WHI Memory Study (WHIMS) reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older, in both the estrogen alone and estrogen plus progestin arms. It is unknown whether these findings apply to younger postmenopausal women.

The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer.

Estrogens with or without progestins should be prescribed at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman.


Premarin Vaginal Cream should not be used in women with any of the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or a history of breast cancer; known or suspected estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism, or a history of these conditions; active arterial thromboembolic disease (e.g., stroke, myocardial infarction), or a history of these conditions; anaphylactic reaction or angioedema with Premarin Vaginal Cream; liver dysfunction or disease; thrombophilic disorders; pregnancy.

The WHI estrogen plus progestin sub-study reported a statistically non-significant increased risk of ovarian cancer. A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown.

Estrogens increase the risk of gallbladder disease. Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs. Monitor thyroid function in women on thyroid replacement therapy, because estrogens may be associated with increased thyroid binding globulin (TBG) levels.

The most common adverse reactions (≥2%) were headache, pelvic pain, vasodilation, breast pain, leucorrhea, metrorrhagia, vaginitis, and vulvovaginal disorder.

Indication Premarin Vaginal Cream is indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

Please see full Prescribing Information, including BOXED WARNING and Patient Information.

In a prespecified secondary endpoint,

Overall vaginal health was assessed at baseline and week 122

  • Total composite scores increased with Premarin Vaginal Cream from 10.78 to 16.31 (n=139) vs 10.09 to 11.76 with placebo (n=68)

    -​​​​​​​​​​​​​​A total score of ≤15 is consistent with moderate to severe vaginal atrophy 
 

Overall vaginal health was a total composite score of:

  • Moisture
  • Epithelial mucosa
  • Fluid secretion
  • Vaginal rugosity
  • Vaginal pH
  • Mucosa color 

No conclusions can be made regarding significance or the individual components comprising the total composite score.
 

‡Genital Health Clinical Evaluation is a tool used to measure overall vaginal health by using a total composite score of the parameters listed above. Individual components were not analyzed separately. 

Your Cart is Empty

Please make a selection from the Samples and/or Savings Card(s) available to you.

Add Items to CartReturn to Home